← All stories
Markets
PTC takes a chance on Sangamo’s Fabry disease gene therapy
Wall Street analysts view the deal as a risky, high-reward bet on a treatment that’s nearing a possible regulatory approval and could be superior to existing medications.
Covered by 1 outlet
All coverage · 1 article